First Biennial Scientific Conference on Medicines Regulation in Africa

[December 2 – December 3, 2013]
Building Partnerships for Sustainable Capacity Development in Medicines Regulation in Africa

Johannesburg, South Africa
The NEPAD Agency in collaboration with the World Health Organization (WHO) and the organisational support of US-Food and Drugs Administration (USFDA) and the Drugs for Neglected Diseases initiative (DNDi) hosted the First Biennial Scientific Conference on Medicines Regulation in Africa in Johannesburg, South Africa.

ASTMH 2013

[November 13 – 17, 2013]
American Society of Tropical Medicine and Hygiene, 62nd Annual Meeting
Washington DC, United States
DNDi co-sponsored a side event on R&D for Chagas disease, presented two posters and was involved in one symposium.

Three Neglected-Disease Treatments Newly Added to WHO Essential Medicines List for Paediatric Use

[Geneva, Switzerland – 11 July 2013]
Resulting from DNDi’s paediatric R&D, the treatments will improve the management of deadly malaria, African sleeping sickness, and Chagas disease in children
This week the World Health Organization (WHO) released its newly updated 4th WHO Model List of Essential Medicines for Children (EMLc), in which three treatments developed by the Drugs for Neglected Diseases initiative (DNDi) and its partners have now been included. One treatment was also added to the 18th WHO Model List of Essential Medicines (EML) for adults.

International AIDS Society Conference 2013

[June 30 – July 3, 2013]
7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention
Kuala Lumpur, Malaysia
The world’s largest open scientific conference on HIV/AIDS was held Kuala Lumpur, Malaysia. DNDi co-hosted a session on closing the treatment gap for children living with HIV.

Ten Years of Health Innovation in Africa: Progress Made But Sustained Engagement and Partnership Needed

[Nairobi, Kenya – 5 June 2013]
Days after two landmark resolutions were adopted at the World Health Assembly – on neglected tropical diseases and on research and development (R&D), financing and coordination for the health needs of developing countries – over 400 scientists, representatives and ministers of health, ambassadors, national control programme representatives, African regulators, health workers, public health experts, and activists from 21 African countries and 10 others from around the world gather in Nairobi to take stock of health innovation for neglected diseases in Africa over the past decade. While progress has been made, and certain diseases are targeted for elimination, the need for strong leadership, coordination, and sustainable funding is as pressing as ever and is critical to achieving much-needed breakthroughs.

A Decade of R&D for Neglected Diseases in Africa

[June 4-5, 2013]
Endemic Country Research and Development for Patient Access
Nairobi, Kenya
On the occasion of DNDi’s 10th anniversary, DNDi and founding partner KEMRI brought together key African decision-makers and public health actors for this special event to explore the challenges and opportunities for research & development for neglected diseases in Africa – past and future!

G-FINDER Report 2012

[3 December,  2012]
This year’s G-FINDER Report provides a survey of global investment into research and development (R&D) of new products for neglected diseases in 2011. Read a comment by Bernard Pécoul on the report’s findings.

DNDi-MMV press release: Open Access Initiative Reveals Drug Hits for Deadly Neglected Tropical Diseases

[Geneva, Switzerland – 13 November 2012]
DNDi screens MMV’s open access Malaria Box, leading to three potential drug classes to treat sleeping sickness and leishmaniasis, which threaten the lives of millions throughout sub-Saharan Africa and pockets around the world
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi’s screening of MMV’s open access Malaria Box. The resulting DNDi screening data are among the first data generated on the Malaria Box to be released into the public domain, exemplifying the potential of openly sharing drug development data for neglected patients.

Cipla-DNDi Press Release: WHO Prequalifies A New Artemisinin-Based Combination Treatment (ACT) for Malaria. Artesunate-Mefloquine Fixed-Dose Combination (ASMQ FDC) to be rolled out throughout Asia

[Kuala Lumpur, Malaysia, Mumbai, India, and Geneva, Switzerland – 3 October 2012]
Cipla, one of the leading generic pharmaceutical companies, along with the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) today announced the prequalification of the fixed dose combination (FDC) of Artesunate (AS) and Mefloquine (MQ) – ASMQ FDC – by the World Health Organization (WHO). This Cipla-manufactured ASMQ FDC is the first artesunate-mefloquine FDC to be prequalified by WHO and is recommended for the treatment of malaria.
[Malay]

Arcabouço Sustentável de P&D é Necessário para Responder às Necessidades Essenciais de Saúde dos Países em Desenvolvimento

[Genebra, Suíça – 21 de maio de 2012]
A DNDi Dá as Boas-Vindas às Recomendações dos Especialistas da Organização  Mundial da Saúde para Iniciar as Negociações para uma Convenção de P&D na Assembleia Mundial da Saúde
Depois de um processo de uma década de análise e deliberações sobre as formas de melhor atender às necessidades de saúde dos países em desenvolvimento, um relatório divulgado recentemente pelo Grupo Consultivo de Especialistas em Pesquisa e Desenvolvimento: Financiamento e Coordenação (CEWG, na sigla em inglês) será discutido esta semana na 65ª Assembleia Mundial da Saúde (item 13.14 da agenda). A iniciativa Medicamentos para Doenças Negligenciadas (DNDi), uma organização de pesquisa e desenvolvimento (P&D) sem fins lucrativos, dá as boas-vindas à conclusão dos especialistas de que “o tempo chegou para os Estados-Membros da OMS iniciarem um processo conducente à negociação de um acordo vinculativo em P&D relevante para as necessidades de saúde dos países em desenvolvimento”.
[English] [Español]